Considering that no FDA-approved drugs currently exist for treatment of either MetS or IGT (pre-diabetes), a peripheral CB1R blocker able to fulfill this role will prove instrumentally useful as a “preventative medicine” approach to reducing the global metabolic disease burden. The gene discussed is CNR1; the disease is diabetes mellitus.